Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
Sign Up to like & getrecommendations! Published in 2024 at "Targeted Oncology"
DOI: 10.1007/s11523-024-01050-3
Abstract: There are few molecular markers driving treatment selection in later lines of treatment for advanced colorectal cancer patients. The vast majority of patients who progress after first- and second-line therapy undergo chemotherapy regardless of molecular… read more here.
Keywords: tfd tpi; analysis; rego; group ... See more keywords
Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Asian Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ajps.2020.01.001
Abstract: Transarterial chemoembolization (TACE) has been widely introduced to treat hepatocellular carcinoma (HCC) especially for unresectable patients for decades. However, TACE evokes an angiogenic response due to the secretion of vascular endothelial growth factor (VEGF), resulting… read more here.
Keywords: hepatocellular carcinoma; loaded poly; rego; poly lactide ... See more keywords
Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3121
Abstract: 3121 Background: TEXCAN, a prospective phase II GERCOR study of treatment with REGO in chemorefractory metastatic colorectal cancer (mCRC) patients (NCT02699073) included a prospective pharmacokinetic (PK) ancillary study aiming to investigate correlations between OS and… read more here.
Keywords: patients treated; ratio; rego; metastatic colorectal ... See more keywords
Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e15562
Abstract: e15562 Background: Regorafenib, approved as a monotherapy for refractory metastatic colorectal cancer (mCRC), is recognized for its potential immunomodulatory effects and ability to reverse chemotherapeutic resistance. In response to this, a combination regimen known as… read more here.
Keywords: colorectal cancer; treatment; metastatic colorectal; rego plus ... See more keywords